Vanguard Capital Management
RKDA icon

Vanguard Capital Management’s Arcadia Biosciences RKDA Stock Holding History

Vanguard Capital Management’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.55K Hold
9,644
– – ﹤0.01% 4062
2026
Q1 		$13.3K Buy
+9,644
New +$18.9K ﹤0.01% 4002

Other funds holding RKDA

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Vanguard Capital Management's RKDA Position: Q2 2026 in Review

Vanguard Capital Management held its Arcadia Biosciences (RKDA) position steady in Q2 2026 at 9,644 shares worth $6.55K. The position accounts for ﹤0.01% of the portfolio, ranked #4062.

Vanguard Capital Management first reported a position in RKDA in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.3K in Q1 2026. 17 funds tracked by Wall St. Rank hold RKDA as of Q2 2026.

  • Vanguard Capital Management held 9,644 shares of Arcadia Biosciences worth $6.55K as of Q2 2026.
  • Vanguard Capital Management left its Arcadia Biosciences share count unchanged in Q2 2026.
  • Arcadia Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4062 holding.
  • Vanguard Capital Management first reported a position in Arcadia Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Arcadia Biosciences position peaked at $13.3K in Q1 2026.
  • 17 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.